Overview

The Individualized M(X) Drug-resistant TB Treatment Strategy Study

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized controlled clinical trial comparing treatment success of a gene-derived individualized drug-resistant Tuberculosis regimen to a standard Tuberculosis regimen based on South African National Tuberculosis guidelines.
Phase:
Phase 4
Details
Lead Sponsor:
Centre for the AIDS Programme of Research in South Africa
Treatments:
Aminosalicylic Acid
Amoxicillin-Potassium Clavulanate Combination